HDL-C May Protect Against Cancer in Type 2 Diabetes

This article originally appeared here.
HDL-C May Protect Against Cancer in Type 2 Diabetes
HDL-C May Protect Against Cancer in Type 2 Diabetes

(HealthDay News) — Higher levels of high-density lipoprotein cholesterol (HDL-C) are associated with a decreased risk of cancer among individuals with type 2 diabetes, according to a study published online September 11 in Diabetes Care.

Wenhui Zhao, MD, from the Pennington Biomedical Research Center in Baton Rouge, LA, and colleagues retrospectively analyzed data from a cohort of 14,169 men and 23,176 women with type 2 diabetes. Patients were categorized by HDL-C level to assess cancer risk.

The researchers found that over 6.4 years of follow-up, 3,711 patients with type 2 diabetes were diagnosed with cancer. There was a significant inverse association between HDL-C and the risk of cancer among both men and women. By HDL-C level at baseline, the multivariable-adjusted hazard ratios of cancer were 1.00 for <30; 0.87 at 30–39.9; 0.95 at 40–49.9; 1.01 at 50–59.9; 0.61 at 60–69.9; 0.45 at 70–79.9; and 0.37 at ≥80mg/dL in men (Ptrend=0.027). For women, the corresponding hazard ratios were 1.00, 0.98, 0.88, 0.85, 0.84, 0.86, and 0.84 (Ptrend=0.025). The association remained when stratified by race, body mass index, smoking status, or medication use; however, the inverse association was substantially weakened after excluding patients who died of or were diagnosed with cancer during the first two years of follow-up.

"The study suggests an inverse association of HDL-C with cancer risk among men and women with type 2 diabetes, whereas the effect of HDL-C was partially mediated by reverse causation," the authors write.

Abstract
Full Text (subscription or payment may be required)